Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eisai Aricept (donepezil) shows no hepatotoxicity in Phase III trials; NDA filed March 29.

Executive Summary

EISAI ARICEPT FOR ALZHEIMER's SHOWS NO HEPATOTOXICITY, according to a company presentation of Phase III data at the American Academy of Neurology meeting in San Francisco March 26. Tokyo-based Eisai announced that Eisai America filed an NDA for Aricept (donepezil, E2020) on March 29. The filing is on schedule with the goal discussed by U.S. co-promotion partner Pfizer in 1994 ("The Pink Sheet" Dec. 5, 1994, T&G-5). Pfizer Exec VP Henry McKinnell said at a Financial Times conference in London that the NDA for the selective acetylcholinesterase inhibitor may get accelerated registration at FDA.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS027948

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel